Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Capital Leases (2021 - 2024)

Lexaria Bioscience's Capital Leases history spans 4 years, with the latest figure at $109319.0 for Q3 2024.

  • Quarterly results put Capital Leases at $109319.0 for Q3 2024, down 19.72% from a year ago — trailing twelve months through Aug 2024 was $109319.0 (down 19.72% YoY), and the annual figure for FY2024 was $109319.0, down 19.72%.
  • Capital Leases for Q3 2024 was $109319.0 at Lexaria Bioscience, down from $115327.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $142587.0 in Q2 2023 to a low of $7401.0 in Q3 2022.
  • The 4-year median for Capital Leases is $118906.5 (2024), against an average of $101599.9.
  • The sharpest move saw Capital Leases crashed 85.19% in 2022, then skyrocketed 1739.93% in 2023.
  • Year by year, Capital Leases stood at $49989.0 in 2021, then crashed by 85.19% to $7401.0 in 2022, then skyrocketed by 1649.99% to $129517.0 in 2023, then dropped by 15.59% to $109319.0 in 2024.
  • According to Business Quant data, Capital Leases over the past three periods came in at $109319.0, $115327.0, and $122486.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.